Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Non-Current Assets (2020 - 2025)

Tango Therapeutics has reported Other Non-Current Assets over the past 6 years, most recently at $303000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $303000.0 for Q4 2025, up 7475.0% from a year ago — trailing twelve months through Dec 2025 was $303000.0 (up 7475.0% YoY), and the annual figure for FY2025 was $303000.0, up 7475.0%.
  • Other Non-Current Assets for Q4 2025 was $303000.0 at Tango Therapeutics, down from $2.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for TNGX hit a ceiling of $4.0 million in Q1 2022 and a floor of $1000.0 in Q1 2025.
  • Median Other Non-Current Assets over the past 5 years was $2.6 million (2024), compared with a mean of $2.4 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 20952.63% in 2022 and later crashed 99.96% in 2025.
  • Tango Therapeutics' Other Non-Current Assets stood at $19000.0 in 2021, then surged by 20952.63% to $4.0 million in 2022, then decreased by 15.0% to $3.4 million in 2023, then crashed by 99.88% to $4000.0 in 2024, then skyrocketed by 7475.0% to $303000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $303000.0 (Q4 2025), $2.1 million (Q3 2025), and $310000.0 (Q2 2025) per Business Quant data.